/
Reactive ATP and MINERVA Reactive ATP and MINERVA

Reactive ATP and MINERVA - PowerPoint Presentation

liane-varnes
liane-varnes . @liane-varnes
Follow
396 views
Uploaded On 2018-09-21

Reactive ATP and MINERVA - PPT Presentation

Reactive ATP allows for multiple deliveries of programmed ATP therapies in response to two clinically relevant events Change in the arrhythmia rhythm cycle length or regularity Elapsed period of ID: 674458

reactive atp dddrp control atp reactive control dddrp mvp atrial dddr change arm rhythm aatp relative hospitalizations minerva reduction programmed interval risk

Share:

Link:

Embed:

Download Presentation from below link

Download Presentation The PPT/PDF document "Reactive ATP and MINERVA" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Reactive ATP and MINERVASlide2
Slide3

Reactive

ATP allows for multiple deliveries of programmed ATP therapies in response to two clinically relevant events:

Change in the arrhythmia

rhythm

(cycle length or regularity)Elapsed period of time

Atrial Reactive ATP OverviewSlide4

Atrial Reactive ATP Programming

Rhythm Change

options:

On/Off

Time Interval

options:

Off, 2

hrs

…48

hrsSlide5

Reactive

ATP – Rhythm Change

If Rhythm Change is enabled:

ATP Therapy “bins” are automatically created by the device based upon whether 1 or 2 zones for AT/AF detection are programmed

The full set of programmed ATP therapies (Rx1, Rx2, Rx3) is available for each bin and for each zone

Regular

Irregular

Regular

IrregularSlide6

Treated AT/AF Programmer ViewSlide7

Evolution of Reactive ATPSlide8

Example of Changing Atrial ArrhythmiasSlide9
Slide10

Reactive

ATP ExampleSlide11

Another Reactive ATP ExampleSlide12

MINERVA Study

n=385

n=383

n=398Slide13

MIN

imiz

E

Right Ventricular pacing to prevent Atrial fibrillation and heart failure studyPrimary objective is to compare the Control DDDR to DDDRP+MVP arms at 2 years using the composite clinical endpoints of

All Cause Death

CV Hospitalizations

Permanent AF

MINERVASlide14
Slide15
Slide16

61% relative reduction between DDDRP + MVP arm and Control DDDR (p = 0.003)Slide17

Risk of AF >7 Days and

aATP

Efficacy

I

mplies

that

aATP

is a driving force behind the resultsSlide18

Primary End Point

2 year composite of death, CV hospitalizations, and permanent AF in DDDRP + MVP arm vs. Control DDDR (26% relative risk reduction, p = 0.04)

End point driven by slowing progression of AF

61% relative reduction between DDDRP + MVP arm and Control DDDR (p = 0.004)

Rates for HCU to AF (hospitalizations, ER visits, atrial CVs) lower in DDDRP + MVP arm compared to Control DDDRMINERVA Key ResultsSlide19

Pacing thresholds rise as the coupling interval is reduced

High outputs designed to maximize the ability to capture all coupling intervals during ATP

1000

aATP

per month decreases longevity by less than 3%Longevity